Growth hormone peptides: what the evidence shows

Do peptides help with growth hormone deficiency and GH secretagogue use?

6 peptides are graded for growth hormone deficiency and GH secretagogue use on this page. The strongest grade is human RCT evidence, for tesamorelin, sermorelin, CJC-1295, and MK-677 (ibutamoren). Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for growth hormone deficiency and GH secretagogue use?

Confirm diagnosis with stimulation testing; recombinant human growth hormone replacement for documented deficiency; treat the underlying cause.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for growth hormone deficiency and GH secretagogue use?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Growth hormone deficiency and GH secretagogue use with evidence grades
Peptide	Evidence for this use	Note
Tesamorelin	Evidence: Human RCT evidence	FDA approved as Egrifta; 15 to 18% reduction in visceral fat over 26 weeks in HIV lipodystrophy trials. [3]
Sermorelin	Evidence: Human RCT evidence	Formerly FDA approved (Geref) for pediatric GH deficiency; product withdrawn for commercial reasons; compounded widely. [2]
CJC-1295	Evidence: Human RCT evidence	Small randomized, placebo-controlled studies in healthy adults raised GH and IGF-1 (surrogate endpoints only); no trial in growth hormone deficiency; development halted; removed from FDA Category 2 list in April 2026. [2]
MK-677 (ibutamoren)	Evidence: Human RCT evidence	Not a peptide (oral small molecule ghrelin agonist); human trials in older adults; not approved. [2]
Hexarelin	Evidence: Human observational evidence	Small human pharmacology studies; not approved. [2]
Ipamorelin	Evidence: Animal-only evidence	Human data are single dose pharmacology studies and an intravenous postoperative ileus trial that do not raise the grade for the marketed use; development stopped; listed by FDA as a withdrawn 503A nomination since April 2026. [2]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for growth hormone deficiency and GH secretagogue use?

Tesamorelin, sermorelin, CJC-1295, and MK-677 (ibutamoren) have the strongest evidence among the peptides graded here, at human RCT evidence. Tesamorelin: FDA approved as Egrifta; 15 to 18% reduction in visceral fat over 26 weeks in HIV lipodystrophy trials. Sermorelin: Formerly FDA approved (Geref) for pediatric GH deficiency; product withdrawn for commercial reasons; compounded widely. CJC-1295: Small randomized, placebo-controlled studies in healthy adults raised GH and IGF-1 (surrogate endpoints only); no trial in growth hormone deficiency; development halted; removed from FDA Category 2 list in April 2026. MK-677 (ibutamoren): Not a peptide (oral small molecule ghrelin agonist); human trials in older adults; not approved. [2] [3]

Is any peptide FDA approved for growth hormone deficiency and GH secretagogue use?

Tesamorelin is an FDA approved drug, but an approval covers only the indications on that label, so check the label before assuming it applies to growth hormone deficiency and GH secretagogue use. The other peptides graded here are not FDA approved. [3] [4]

Has any peptide been tested in a randomized trial for growth hormone deficiency and GH secretagogue use?

Yes, for tesamorelin, sermorelin, CJC-1295, and MK-677 (ibutamoren). Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [3]

From the blog

CJC-1295 side effects: what the human studies reported
CJC-1295 side effects in small human studies included injection site reactions, headache, flushing, diarrhea, and a faster heart rate. It has no FDA approval and no lawful compounding path.
Sermorelin vs HGH: mechanism, evidence, and legal status
Sermorelin signals the pituitary to release growth hormone; HGH (somatropin) is the hormone itself. Only somatropin is FDA approved today, and anti-aging use of either is off-label.
Tesamorelin vs HGH: how they differ and which is approved
Tesamorelin (Egrifta) signals the pituitary to release growth hormone and is approved for HIV-associated belly fat; HGH (somatropin) is the hormone itself, approved for other conditions.
Tesamorelin vs sermorelin vs ipamorelin: evidence and legality
Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.

Peptides for growth hormone deficiency and GH secretagogue use: what the evidence shows

At a glance